top of page
KRAS Cancer News & Updates
SPARK study: Studying Pathways of Resistance in KRAS-12C driven Cancers
Brief Summary “Up to 250 patients from anywhere in the United States can remotely consent and participate  to have plasma drawn locally...
fireflyannf
Oct 13, 2024
Revolution Medicines: RMC-6236 Pancreatic Cancer Update to Support Pivotal Phase 3 Trial
Rev Med reports out on the 46% of the pancreatic cancer patients who were enrolled in NCT05379985 (54% of patients are NSLC or other...
fireflyannf
Jul 24, 2024
KRAS Kickers featured at AACR
American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the...
Terri Conneran KRAS Kickers
Apr 9, 2021
Adagrasib for Patients With Advanced KRAS G12C–Mutated NSCLC
Treatment with the KRAS G12C inhibitor adagrasib showed clinical activity in patients with advanced non–small cell lung cancer (NSCLC)...
Terri Conneran KRAS Kickers
Mar 25, 2021
Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung Cancer
Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced...
Terri Conneran KRAS Kickers
Mar 24, 2021
Lilly Announces Details of Presentations at 2021 American Association for Cancer Research
Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at...
Terri Conneran KRAS Kickers
Mar 11, 2021
Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial
Eli Lilly has rejoined the KRAS race months after toxicity forced it to dump its first candidate. The Big Pharma is set to enter phase 1...
Nick Paul Taylor
Mar 11, 2021
The Epic Battle with Cancer's 'Death Star'
David Cox Forty years after the mutant genes that cause the deadliest cancers were discovered, drugs that target them could be approved...
David Cox
Mar 6, 2021
How Scientists Shot Down Cancer’s ‘Death Star’
Gina Kolata No drug could touch a quivering protein implicated in a variety of tumors. Then one chemist saw an opening. After 40 years of...
Gina Kolata
Feb 5, 2021
Sotorasib Provides Durable Clinical Benefit for Patients with NSCLC and KRAS Mutations
IASLC Exciting New Research to be Presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer’s...
Terri Conneran KRAS Kickers
Jan 25, 2021
The Improbable Targeted Therapy: KRAS as an Emerging Target in Non-Small Cell Lung Cancer
KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC). It was previously thought to be an...
Terri Conneran KRAS Kickers
Jan 19, 2021
Honoring Jerry Cornelius of Canyon Creek. Family Man, Texan, Craftsman
https://www.kraskickers.org/post/honoring-jerry-cornelius-of-canyon-creek-family-man-texan-craftsman
Cancer Treatment & Clinical Trial Eligibility: What Patients Need to Know
Once you know your options, the next question is: Am I eligible? Here’s how doctors typically determine if a patient qualifies for a clinical trial or specific therapy—regardless of cancer type.
6 things that matter...
What Every Cancer Patient Should Know About Today’s Treatment Options
..just been diagnosed—or are navigating next step—you’re not alone. Cancer care has changed dramatically in the last decade. Today, you may have more treatment choices than ever before. This post is designed to help you understand your options and feel confident asking the right questions.
bottom of page